Merck Serono has signed a deal with Opexa Therapeutics for the option to acquire exclusive development and marketing rights to Opexa's Tcelna, or imilecleucel-T, an experimental personalized T-cell treatment for multiple sclerosis, in all countries except Japan. Opexa received $5 million upfront, and would get an additional $25 million or $15 million if Merck exercises the option. Opexa is also eligible to receive as much as $195 million in milestone fees plus sales royalties.
Sentiment: Strong Buy
After reading some of the post it was clear that it to awhile for wall st to see that this is a good thing. LOL Small promising bio companies with hot drugs in the pipeline is where you want to put your money. They will hold up on a bad tape and go up on a good one. GL2ALL